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  The peak and valley problems caused by oral administration, injection or other conventional 
methods, call for developing systems that can deliver therapeutics more effectively. As one 
of the techniques, diffusion-controlled drug release membranes have significant interest due 
to great ease with which they can be designed to achieve near-zero
th
-order release kinetics.  
Since diffusion is the rate-limiting step in these systems, determining the permeability and 
diffusivity of drug molecules in the membrane is therefore important in evaluating drug 
release performance.  
  This study focuses on the Membrane Permeation Controlled Release (MPC) system, which 
involves a non-porous (dense) membrane, comprising of two biopolymers, sericin and 
chitosan. Ciprofloxacin hydrochloride and (+)-cis-diltiazem hydrochloride were used as 
hydrophilic model drugs, and nitro-2-furaldehyde semicarbazone (Nitrofurazon) was used as 
a hydrophobic model drug. Permeation experiments were carried out in a semi-infinite 
reservoir/receptor system to simulate in-vitro drug release.  
  The intrinsic permeability and diffusivity (P, D) of the drugs through the membranes were 
determined using a modified time-lag method based on short time permeation and mass 
balance method based on long time permeation.  The partition coefficients Kd of the drugs in 
the membranes and the swelling degree of the membranes were determined by 
sorption/desorption experiments. The diffusivities of the drugs were also determined from the 
sorption/desorption kinetics. Over the experimental ranges tested, the drug concentration and 
 
 iv 
membrane cross-linking did not have significant effects on these parameters presumably due 
to the relatively low drug concentrations and mild crosslinkings of the membranes. The 
diffusivity coefficients of ciprofloxacin hydrochloride, (+)-cis-diltiazem hydrochloride and 
nitrofurazon in the membranes were found to be in the range of                          
cm
2
/s,                           and                          (cm2/s), respectively,  
and their permeability coefficients were in the range of                            and 
                (cm2/s), respectively. The partition coefficients were determined to be 
around 0.91±0.21, 25±0.12 and 26±0.31, respectively. The diffusivity coefficients determined 
from sorption experiments for ciprofloxacin hydrochloride, diltiazem hydrochloride and 
nitrofurazon were found to be in the range of                         ,              
         and                        (cm2/s), respectively. Also the diffusivity 
coefficients determined from sorption experiments for ciprofloxacin hydrochloride, diltiazem 
hydrochloride and nitrofurazon were in the range of              ,               and 
              (cm2/s), respectively. Nonetheless the differences in the diffusivities 
calculated from permeation and sorption/desorption experiments are considered to be 
acceptable, in view of the different experimental techniques used in this work, for the 
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Chapter 1  Introduction 
  Controlled drug release technologies have been emerging in the past three decades and have 
been commercialized in some administrative pharmaceutical therapies. The safety and 
therapeutic efficiency of drugs are improved by controlling the rate of release, 
biodegradation and targeting the specific site. These technologies help avoid‎ the‎“peak‎and‎
valley”‎problems‎caused‎by‎oral‎or‎injection therapy and provide more effective treatment by 
delivering drugs steadily in the body over a long period of time (Jin and Song, 2006). 
  There are two main physical methods of controlled release using polymeric systems 
controlled release studies, including Membrane Permeation Controlled (MPC) release and 
Matrix Diffusion Controlled (MDC) release. In the latter, the release profile of drugs usually 
depends upon such parameters as initial drug loading, size of the matrix, pH of medium and 
type of mechanism involved (Singh and Ray, 1999). In the membrane permeation controlled 
(MPC) systems, where the drug is surrounded by a polymeric membrane and diffusion of the 
drug through the membrane is the rate limiting step, determining the intrinsic permeation 
parameters such as diffusivity, permeability and partition coefficients is therefore important  
for evaluation and analysis of drug release profiles (Chen et al., 2010).  
Using of polymeric materials either stand alone or as blends for controlled drug release 
systems have many major advantages, including facilitating and adjustment of a desired drug 
release pattern, improvement in mechanical properties and controlling drug release 
mechanisms, improving film formation, protecting the chemical stability of drug, and 
developing strategies for site targeting( Langer and Peppas, 1981). 
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  Sericin is a natural macromolecular protein derived from silkworm Bombyx mori. Sericin 
protein is very useful because of its unique properties. Resistance to oxidation, and UV 
radiation, absorbance and releases of moisture and its antibacterial effects made this protein 
unique and widely applicable. Sericin has the ability to be cross-linked, copolymerized, and 
blended with other macromolecular materials (e.g. chitosan), to provide materials with 
improved properties. The materials modified or blended with sericin or sericin composites 
are well-known as biodegradable and biocompatible materials that can be used for forming 
articles, functional membranes, fibers, and fabrics (Zhang, 2002). 
   Chitosan, a modified natural biopolymer with a special structure contains more than 5,000 
glucosamine units and is commercially produced from shrimp, shell fish, and crab shell by 
alkaline deacetylation. Because of the chemical nature of chitosan, it is ready for covalent 
and ionic modifications which allow extensive adjustment of mechanical and biological 
properties. Chitosan is an interesting biopolymer, and it can easily be made into a variety of 
forms including membranes, sponges, fibers, beads, powders and solutions. This biomaterial 
has a specific chemical structure as a linear polyelectrolyte with a high charge density as well 
as reactive hydroxyl and amino groups (Muzzarelli et al., 1999, Stoilova et al., 2001, Wang 
et al., 2003, Zhang M. et al., 2003, Kenawy et al., 2005). 
  Diltiazem-HCl is one of the calcium channel blockers and is used clinically as a drug choice 
for cure of hypertension and angina pectoris. Ciprofloxacin-HCl is a synthetic 
chemotherapeutic antibiotic and used for bacterial infections.  Nitrofurazon is also an 
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antibiotic used most commonly in the form of ointments. The drugs were used as model drug 
compounds in this study. 
  This research focused on the preparation and application of novel sericin/chitosan blend 
membranes for controlled release of drugs. This sericin/chitosan blend was tested for 
controlled release of drugs for the first time and the main objective of this work was to 
evaluate the intrinsic permeation properties (e.g. diffusivity, permeability and partition 
coefficients) of three model drugs using different measurement techniques, including 
modified time-lag and mass balance methods as well as sorption and desorption kinetic 
studies.  
Scope of Thesis 
  This thesis work covers the following aspects to provide a systematic study of controlled 
release of model drugs using sericin/chitosan blend membranes: 
Chapter 1 gives an introduction to polymeric controlled release systems, polymeric materials 
used in controlled release of drugs, and the model drugs used in this study. 
Chapter 2 is a review of the background of controlled release of drugs, polymers and 
biopolymers used for controlled release, and methods for evaluating the intrinsic permeation 
parameters of drugs in the membranes.  
Chapter 3 deals with the materials, experimental setup and procedures used in this study 
Chapter 4 presents the results obtained from this study and discussion of the results.  
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Finally, the general conclusions derived from the study, and recommendations of future work 
to be done for further studies are presented in chapters 5 and 6, respectively. The sample 
calculations and some additional experimental data are presented in the appendix.  
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Chapter 2   Literature Review 
2.1 Controlled Release Systems 
  Recent controlled-release applications include a vast variety of areas including medical, 
agricultural, food and household products. Controlled-release is very important in many 
fields. For instance, in agriculture, the controlled release of pesticides and fertilizer using 
polymeric films makes it possible to shorten treatment times, which leads to labor saving and 
the prevention of phytotoxicity and excess release of agrochemicals into the environment.  
  The history of controlled release of drugs goes back to the mid 1960s when Judah Folkman, 
a MD at University of Harvard, discovered that a silicone tube could be implanted in rabbits 
and acted as a constant-rate drug delivery device. It was the first time that zero
th
-order 
controlled drug delivery implant in-vivo was suggested (Hoffman, 2008). For a long period 
of time, researchers have been focusing on the synthesis or discovery of potent drugs with 
new or improved biological activity. While this continues to be an important area of research, 
increasing attention is being devoted to the manner in which these drugs are delivered. One 
of the areas in which chemists and chemical engineers are contributing to is the design and 
development of systems which controls drug delivery. Such delivery systems offer numerous 
advantages over conventional methods. Since the 1980s, a major focus of drug-related 
research has been devoted to drug delivery. Recent growth of significant interest in 
controlled-release relates to solving the general dose-delivery problems. The “peak and 
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valley” problems, caused by oral administration, injection or other conventional methods, 
call for developing systems that can deliver therapeutics more effectively.  
  In the past three decades, many polymer- drug systems were investigated. Using polymeric 
carriers for drugs may lead to a continuous release of drug for a long period of time. One way 
that has been considered as a means of controlling drug delivery is the incorporation of drugs 
in solid polymers. Controlled-release polymeric systems can be classified based on the 
mechanism of drug release. Diffusion of drug molecules in the polymer may be the rate 
limiting step of the release process. The systems designed based on the diffusion of drugs in 
polymers are called diffusion-controlled systems. If chemical reaction at the interface of the 
polymer and the dissolution medium can be the rate controlling step it will be called a 
chemically-controlled system. Countercurrent diffusion of dissolution medium at constant 
penetration rate in the polymer matrix can also be the rate limiting factor, and such a system 
is called swelling-controlled system. Sometimes an external field is responsible for the 
release of drugs and magnetically-controlled release systems are an example of such systems 
(Langer and Peppas, 1981).  
2.2 Diffusion-Controlled Systems 
Diffusion-controlled systems are the most widely used. Several diffusion controlled release 
systems have been developed and marketed since the 1970s, though first trace of these 
studies goes back to the early 1960s. There are two types of diffusion controlled release 
systems, including Matrix Diffusion Controlled systems (MDC) and Membrane Permeation 
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Controlled systems (MPC) or Reservoir systems. MDCs may be divided into two categories: 
(i) degrading polymer matrix, which degrades or dissolves in the system, and (ii) non-
degrading polymer matrix where drug molecules diffuse through the polymer. MPCs may 
also be divided into two categories depending whether non-porous membranes or micro-
porous membranes are used in the controlled release systems (Jain et al., 2003; Langer and 
Peppas, 1981). Figure 2-1 illustrates the diffusion controlled systems schematically. 
 
 
Figure ‎2-1 Idealized diffusion-controlled reservoir release system (top),  




2.3 Reservoir Systems (Membrane Controlled Permeation) 
   In such systems, a polymeric film surrounds the drug and the diffusion of the drug through 
the film is the rate limiting step controlling the release rate (See Figure2-1). Membranes, 
capsules, microcapsules, and hollow fibers can be used in these systems as the surrounding 
polymer. Among these, membranes and polymeric films have proven to be of greatest value 
and attracted most attentions in controlled-release applications. In fact, most products 
developed or marketed to date are membrane-enclosed reservoir systems. At present, a wide 
range of polymers (both synthetic and natural biopolymers) are used for this type of release 
systems. These polymers must be relatively inert, do not readily biodegrade, be nontoxic, 
have good tissue biocompatibility, and be generally permeable only to low molecular weight 
solutes, in order to be suitable for clinical use. A key problem in design of such a system, 
from a pharmaceutical point of view, is to reach the zero
th
-order release rate. The most 
important advantage of membrane controlled permeation systems is the ease with which they 
can be designed to achieve the zero
th
-order release kinetics. Diffusion through membranes 
has been investigated extensively and many reviews have been published (Crank, 1975; 
Crank and Park 1968).  
2.4 Polymers Used for Controlled Drug Release 
Because of the vast variety of polymer structures, classifying polymers for controlled release 
applications is not an easy job. Generally, the polymers may be classified into biodegradable 
and non-biodegradable. Biodegradable polymers have attracted significant attention for drug 
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delivery systems because of their excellent biocompatibility. On the other hand, for in vivo 
applications non-biodegradable polymers need retrieval after introduction into the body. 
Table 2-1 summarizes the polymers mostly used in controlled release systems recently. 





-order controlled by diffusion from matrix. 
Polypropylene Ophthalmic drug delivery applications. 
Polyvinyl chloride Membrane devices for controlled release of volatiles in the 
air and non-volatile into solutions. 
Polyvinyl alcohol Bioadhesive hydrogels. 
Polyethylene-vinyl acetate Ultrasound-stimulated release for cancer chemotherapy 
Polyacrylic acid Bioadhesive polymer. 
Polyacrylamide Component of photosensitive delivery 
Polyethylene glycol Used as Polymer-drug conjugates 
Poly(dimethyl siloxane) Controlled release of rifampicin 
Poly (L-lactic acid) Biomedical application (biodegradable) 
Cyclodextrin  Drug penetration enhancer-Drug shell 
Chitosan  Tablet coatings-Transdermal patches 
Sericin  Wound healing-cosmetics 




   Sericin is a natural silk protein, which is a highly hydrophilic macromolecule and derived 
from silkworm Bombyx mori cocoons in a process called degumming. Sericin is comprised of 
18 amino acids. The molecular weights of sericin protein range from 24 to 400 kDa with 
predominant amino acid groups being serine (40%), glycine (16%), glutamic acid, aspartic 
acid, threonine and tyrosine. Thus it consists of polar side chains of hydroxyl, carboxyl and 
amino groups that enable easy cross-linking, copolymerization and blending with other 
polymers to form improved biodegradable materials (Takasu et al., 2002). Sericin represents 
20-30% of total cocoon weight.  The main role of sericin is to hold and bind the fibroin fibers 
together. Sericin occurs mainly in an amorphous random coil and to a lesser extent, in a β-
sheet structure. The randomly coiled structure easily changes to β-sheet structure, as a 
consequence of repeated moisture absorption and mechanical stretching (Padamwar M. N. et 
al., 2005). 
   Sericin can be divided into three types, based on their solubility. Sericin type A is soluble 
in hot water. It is comprised of 17.32% of nitrogen and amino acids like, serine, threonine, 
glycine, and aspartic acid. Type B contains 16.8% of nitrogen and it turns to type A by acid 
hydrolysis. Sericin type C is the innermost layer, adjacent to fibroin and is insoluble in 
boiling water and can be removed from fibroin by treatment with hot dilute acid or alkali 
solutions. The most abundant molecular conformation of water soluble sericin is random 
coils, whereas the β-sheet structure is more difficult to dissolve in aqueous solutions.  
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  Sericin proteins with lower molecular weights (<20 kDa) or sericin hydrolysates are usually 
used in cosmeticeutical products such as skincare and hair-care products, health products, 
and medications. Sericin with higher molecular weights (>20 kDa) are mostly used as 
medical biomaterials, degradable biomaterials, compound polymers, functional 




   The structure of sericin, especially in the two convertible forms (e. g. water-soluble and 
insoluble) gives it unique properties. Table 2-2 summarizes some properties of sericin. 
Table ‎2-2 Properties of Sericin and Characteristics (Padamwar and Pawar, 2004) 
Property Characteristics 
Gelling property 
Sericin due to its solubility can be in the form of random coil 
or β-sheet structure. Random coil is soluble in boiling water 
and by decreasing the temperature the random coil turns to β-
sheet structure. So it converts to a gel form. 
Sol-Gel Transition 
Sericin has shown a sol-gel property due to its ease of 
dissolution in water at 50-60ᵒC and turning to gel form as 
cooled. 
Isoelectric pH 
As there are more acidic than basic amino acid residues the 
isoelectric point of sericin is about 4.0. 
Solubility of sericin 
 
By transforming of sericin structure from random coil into β 
sheet, its solubility in water decreases, and will increase by 
addition of poly(Na acrylate). Its solubility in water decreases 
as polyacrylamide, formaldehyde, or resin finishing agents are 
added. 
Molecular Weight 
Extracting sericin using hot water shows molecular weight of 
24,000, whereas sericin extracted by spray-drying have the 
molecular weight of 5,000-50,000. Its molecular weight ranges 
300-10,000 when it is enzymaticly treated, and ranges above 







   Blending sericin with some resins may produce environment-friendly biodegradable 
polymers (Annamaria et al., 1998). Sericin blended with polyurethane foams gives excellent 
moisture absorbing and desorbing properties which turns it to a good sol-gel material 
(Nomura et al., 1995). The sericin/polyurethane blended foam has the moisture 
absorption/desorption capacity of 2-5 times greater than that of the control. The 
polyurethane/sericin blend contains biodegradable sericin segments, and is capable to turn 
into films, fibers, and molded objects (Fujita et al., 1998; Sumitomo et al., 1997; Zhang, 
2002).  
   Membrane separation processes such as reverse osmosis (RO), dialysis, ultra filtration,  and 
microfiltration are worldwide used in many industries including water desalination, 
production of  pure water, and bioprocessing (Chisti, 1998). Sericin can be used to make 
membranes for use in separation processes. For instance, it’s‎ reported‎ by‎ Hirotsu and 
Nakajima (1988) that silk membrane can be used for dehydration of alcohol. It is hard to 
make a pure sericin membrane, but some membranes are reported to be made readily from 
sericin in a cross-linked form, blended with other polymers, or copolymerized with other 
substances. Due to a large number of amino acids with neutral polar functional groups in 
sericin, sericin-containing films are highly hydrophilic. Sericin composite membranes are 
generally permselective for water in an aqueous-organic liquid mixture.  
   As mentioned above pure sericin film is difficult to form, but sericin based films can be 
prepared by attaching to another matrix. Nakajima (1994) showed that sericin films used in a 
liquid crystal can uniformly orient the liquid crystal molecules to provide better quality liquid 
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crystal displays. Also, it is reported that the surfaces of refrigeration equipment can be coated 
by sericin to achieve its antifrosting action (Tanaka, 2001).  
  A silk based wound dressing has been developed by (Tsubouchi, 1999a), which has healing 
effects and can be peeled off without damaging the new tissue. Subsequently, the wound 
dressing was made with a mixture of fibroin and sericin (Tsubouchi, 1999b). Membranes 
made of sericin and fibroin, are as an effective substrate for cell proliferation and adhesion in 
animal cells culture and can be used as in tissue engineering. Minoura et al. (1995) and 
Tsukada et al. (1999) investigated the cell attachment and growth of mammalian cells on the 
films made of sericin and fibroin.  
2.6 Chitosan 
Chitosan is a natural polycationic polymer with properties and characteristics. It contains 
more than 5,000 glucosamine units and is commercially produced from chitin by alkaline 
deacetylation. Chitosan is also found in some microorganisms, yeast and fungi. Chitin, a 
naturally abundant mucopolysaccharide, and the supporting material of crustaceans, insects, 
etc., is well known to consist of 2-acetamido-2-deoxy-β-D-glucose through a β‎ (1→4)‎
linkage. Chitin is a white, hard, non-elastic, nitrogenous polysaccharide (Rabea et al, 2003). 
Chitosan, from deacetylation of chitin, is a linear polysaccharide, composed of glucosamine 
and N-acetyl‎ glucosamine‎ units‎ linked‎ by‎ β‎ (1–4) glycosidic bonds. The content of 
glucosamine is related to the degree of deacetylation. Chitosan is available in a wide range of 
molecular weights and degrees of deacetylation. Depending on the source and preparation 
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procedure, its molecular weight may vary from 300 to over 1,000 kDa with a deacetylation 
degree from 30% to 95% (Dornish et al., 2001; VandeVord et al., 2002). The schematic 
structures of chitin and chitosan and the preparation of chitosan from chitin are illustrated in 
Figure 2-2. 
 
Figure ‎2-2 Preparation of chitosan from chitin (Rabea et al., 2003) 
 
   Chitosan in a crystalline form is normally insoluble in aqueous solutions above pH 7. 
However, it is soluble in most dilute organic acidic solutions at pH<6.0, including acetic, 
formic, tartaric and citric acids. The protonated free amino groups on glucosamine facilitate 
solubility of the molecule. Chitosan has three types of reactive functional groups, an amino 
group and a primary and secondary hydroxyl groups. These functional groups allow 
modification of chitosan by graft copolymerization for specific applications. Chitosan may 
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also be subjected to covalent and ionic modifications which allow for extensive adjustment 
of mechanical and biological properties. Chitosan is an interesting biopolymer since it is 
readily available and can be made into a variety of forms (e. g. membranes, sponges, fibers, 
beads, powders and solutions). Chitosan is a linear polyelectrolyte with a high charge 
density, having reactive hydroxyl and amino groups (Muzzarelli et al., 1999; Stoilova et al., 
2001; Wang et al., 2003; Zhang et al., 2003; Kenawy et al., 2005). Chitosan has also been 
reported for a wound healing biomaterial (Malette et al., 1983). It can also reduces serum 
cholesterol levels (Nagyvary et al., 1987) and stimulate the immune system. Chitosan is an 
excellent flocculent, adhering to negatively charged surfaces with biocompatible, non-toxic, 
biodegradable and fungicidal activities. Furthermore, it is possible to modify chitosan as an 
antimicrobial polymer, making it a very attractive biomaterial.  
    Controlled release technology and drug delivery systems are the emerging sciences of the 
1980s, and they are commercially available for certain therapeutics applications. Designing a 
release system for a target agent into a specific medium for a long time is a key factor for the 
controlled delivery system. Chitosan a natural biopolymer appears to be an ideal candidate 
for controlled release applications. There is a great deal of work reported in literature 
confirming that chitosan is one of the best choices for drug delivery systems.  
Nakatsuka and Andrady (1992) used chitosan blended with poly(vinyl alcohol) (PVA) with 
different degrees of crosslinking in the form of membranes, and they evaluated their 
applications in controlled release of Vitamin B-12. These chitosan membranes showed 
acceptable permeability, diffusivity, and hydrogel properties when crosslinked or blended 
 
 17 
with PVA. Their results showed that the hydration of chitosan hydrogels as measured by the 
swelling ratio can be altered over a wide range, either by crosslinking or by blending with 
PVA. Kim et al. (1992) used crosslinked PVA/chitosan blend membranes for controlled 
release of Riboflavin and Insulin. It is shown that the permeability and diffusivity of the 
blended membranes have pH dependencies and increase with an increase in the glucose 
concentration. In controlled release of Insulin using the membranes, the desired release rate 
can be achieved by means of crosslinking. Jin and Song (2006) reported that the chitosan and 
chitosan/poly(ethylene oxide) blend films crosslinked by genipin are pH sensitive and have 
desirable‎mechanical‎ properties.‎ These‎ characteristics‎ and‎ film’s‎ non-toxic nature make it 
ideal for use in controlled release of drugs. Vitamin B12 and Eleutherococcus Sentisocus were 
used as model drugs. Silva et al. (2006) used fosfosal, an anionic model drug, to study the 
permeability of chitosan membranes to small molecular-weight water-soluble molecules. 
They reported that chitosan modification have a strong influence on the permeability of the 
anionic model drug. Thacharodi and Rao (1993) studied the permeability characteristics of a 
chitosan membrane using an anti-hypertensive drug nifedipine, and they investigated the 
effect of crosslinking on the permeability of membrane. Singh and Ray (1999) modified a 
chitosan membrane by graft copolymerization and used it to study the controlled release of 
glucose as a model drug. They studied the release characteristics of glucose as a function of 
the degree of grafting in the chitosan membranes. The permeability coefficient of glucose 






/s. Berthold et 
al. (1996) used chitosan in a microsphere form as the drug carriers and the release kinetics of 
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model drugs from the microspheres was studied. They found that the drug release from the 
microspheres is dependent on the drug-polymer ratio. Wang et al. (2007) studied the 
controlled release of ciprofloxacin hydrochloride from chitosan/poly(ethylene glycol) blend 
films. Chemical and morphological characterizations confirmed that there is a good 
compatibility between the membrane matrix and ciprofloxacin hydrochloride because of their 
strong interactions (e.g. hydrogen bonding and ionic interactions). The mechanical property 
of the membrane was also good. Their research showed that the loading amount of the drug 
to the membrane can be controlled by the ratio of chitosan/PEG and the degree of 
crosslinking.  




Table ‎2-3 Principal properties of chitosan in relation to its application (Marguerite Rinaudo, 2006) 
Principal applications Principal characteristics 
Surgical sutures Biocompatible 
Dental implants Biodegradable 
Artificial skin Renewable 
Rebuilding of bone Film forming 
Corneal contact lenses Hydrating agent 
Time release drugs for animals and humans Nontoxic, biological tolerance 
Encapsulating material Hydrolyzed by lyzosyme, Wound healing properties, 
Efficient against bacteria, viruses, fungi 
Agriculture Defensive mechanism in plants, Stimulation of plant 
growth, Seed coating, Frost protection, Time release of 
fertilizers and nutrients into the soil. 
Water & waste treatment Flocculant to clarify water (drinking water, pools), 
Removal of metal ions, Ecological polymer (eliminate 
synthetic polymers), Reduce odors 
Food & beverages Not digestible by human (dietary fiber), Bind lipids 
(reduce cholesterol), Preservative, Thickener and 
stabilizer for sauces, Protective, Fungi static, 
antibacterial coating for fruit 
Cosmetics & toiletries Maintain skin moisture, Treat acne, Improve 
suppleness of hair, Reduce static electricity in hair, 
Tone skin, Oral care (toothpaste, chewing gum) 
Biopharmaceutics Immunologic, anti tumor, Hemostatic and 





2.7 Sericin and Chitosan Blend Film 
   Srihanam et al. (2009) have attempted to investigate films from chitosan/sericin blends as 
well as the native sericin and chitosan films. The morphologies of the films were observed 
using Scanning Electron Microscope (SEM). They analyzed the secondary structures of the 
films by FTIR spectroscopy. Also they investigated the transparency of the films using UV-
Visible spectroscopy. The native sericin film showed absorption bands of at 1684 cm
-1
 
(amide I), 1559 cm
-1
 (amide II), while the blend sericin/chitosan film showed wide 
absorption bands at about 1640 cm
-1
 (amide I), 1534 cm
-1
 (amide II) and 1100-1080 cm
-1
. For 
pure chitosan film, the FTIR spectrum showed an absorption band at 1650 cm
-1
 with shoulder 
bands at 1578 and 1103 cm
-1
. These results indicate that the blend film composed of sericin 
and chitosan has an amide I band in the range of the carbonyl groups. It is illustrated in their 
work that sericin and chitosan are compatible. Also they showed that two materials are 
miscible together. The FTIR results indicated that most of the films were composed of 
random coils and‎ β-sheets. It appears that the blend film of sericin and chitosan did not 
change the interamolecular structure when compared to the native films.  
  Sericin-based film properties are dependent on components used to form film, which can 
used to tailor the desired film flexibility and controlling the permeability of the films. Sericin 
is removed as waste during the degumming process of the silk manufacturing. Sericin can be 
utilized to make biofilms as a value-added product developed from the wastes. Therefore it 
represents a significant source of profit, not only having beneficial effect of waste reduction 
for pollution prevention but also having healing effect which accelerates the wound healing 
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process and improving the moisture adsorption of the film. Sericin based film also have 
shown good oxygen permeability which is an essential characteristic for wound dressing or 




2.8 Diffusion in Membranes 
The mathematical model of diffusion in polymers, more specifically in membranes is based 
on the hypothesis that the rate of diffusion through a unit area of the membrane is 
proportional to the concentration gradient of diffusing substance across the membrane. The 
diffusion rate of the penetrant through a membrane is determined by the Fick’s law of 
diffusion. Consider drug diffusion through a flat membrane, shown in Figure 2-3 
 
 







    
  
  
                            
  where   is the rate of molar flux per unit area of the membrane, 
  
  
 is the concentration 
gradient across the membrane, and   is the diffusion coefficient in the membrane. By 
considering the mass balance of an element of volume it can be shown that the differential    
equation of diffusion takes the form: 
  
  
   
   
   
 
   
   
 
   
   
               
 
  where   is constant and independent of concentration. 
  Often diffusion occurs effectively in one direction only. Assuming the concentration 
gradient is one dimensional along the x-axis, the Equation 2-2 reduces to: 
 
           
  
  
   
   
   
                               
 
  Equations 2-1 and 2-3‎ are‎ referred‎ to‎ as‎ Fick’s‎ first‎ and‎ second‎ laws‎ of‎ diffusion‎
respectively.  
  For a constant diffusion coefficient and constant membrane thickness (i.e., there is no 
change in membrane thickness when drug concentration changes during the course of 
permeation), equation 2-1 can be integrated to yield: 
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  where   is the membrane thickness. To maintain a constant flux, the trans-membrane 
concentration difference,    must be kept constant. This can be done by maintaining a 
constant, high drug concentration at the donor side         of the membrane and keep the 
receptor side at sink condition      . To accomplish these conditions, the drug must be 
loaded at a high level. As long as the drug concentration is high enough at the donor side 
compared to receptor, zero
th
-order release will occur. Since diffusion is a key step which 
controls the rate of release in such systems, determination of intrinsic permeation and 
diffusion coefficients of the drug molecules in the membrane is important in design of 
controlled release systems (Langer and Peppas, 1981; Chen et al., 2010). 
  The diffusion of drugs through a membrane can be divided into three stages. At an initial 
stage of permeation, the diffusion is at an unsteady-state and the mass transfer rate and 
concentration profile in the membrane vary with time. This stage is followed by a pseudo-
steady-state permeation when the concentration gradient across the membrane is fully 
developed and both the concentration profile in the membrane and the rate of flow across the 
membrane become constant. The last stage is again an unsteady-state permeation during 
which the drug concentration at the receptor side builds up significantly and the 
concentration gradient in the membrane begins to decreases significantly with time. At this 
stage, the zero
th
-order diffusion kinetics does not hold anymore. 
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2.8.1 Time-Lag Method 
  At the instant that the diffusion starts at one side of the membrane and prior to 
establishment of a constant concentration gradient across the film, both concentration profile 
in and the diffusion rate across the membrane vary with time. Assume that the diffusion 
coefficient of the drug in the membrane is constant and independent of concentration. If the 
membrane is initially free of any drug molecules and the drug diffused to the receptor side is 
continuously removed, the total amount of drug   passing through the membrane at time   is 
given by (Crank and Park 1968): 
 











     
  
    
       
  




  where   is the membrane thickness,     is drug concentration in the membrane at the donor 
side, and A is the membrane area.  
The graph of   versus   is illustrated in Figure 2-4, which shows the accumulative amount of 
drug released at different times. As time passes the permeation gradually reaches the steady-




Figure ‎2-4 Quantity of permeant received in the receptor side of the membrane to illustrate the time-lag  
due to initial transient permeation (Chen et al., 2010) 
 
 The rate of pseudo steady state permeation through the membrane thus becomes  
             
     
 
   
  
  
                    
 which yields a straight line, with an intercept,  , when interpolated on the t-axis.   is called 
time-lag (Crank and Park 1968), and is given by  
                             
  
  
                               
  In non-porous polymer films (dense membranes), drug transport across the film occurs via a 
solution-diffusion mechanism. The drug passes through the membrane by a mechanism 
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involving drug dissolution on the membrane surface, followed by drug diffusion across the 
membrane and then drug release to the receptor side. Assuming a linear relationship between 
the drug concentration in the membrane at donor side     and the equilibrium drug 
concentration in the solution   , that is,         , then Equation 2-7 can be rewritten as 
              
    
 
   
  
  
                           
where,   is the permeability coefficient of the drug through the membrane at the steady state 
and it is equal to product of diffusivity coefficient and partition coefficient of the drug in the 
membrane: 
                                                                    
The permeability coefficient   can therefore be determined from the slope of pseudo steady-
state segment of the (  vs.  ) plot. The partition coefficient   can further be calculated from 
Equation 2-9. It must be mentioned that the time-lag calculated using Equations 2-7 is the 
intercept of the (  vs.  ) plot on the t-axis obtained by extrapolation of steady state 
permeation data based on Equation 2-8. As mentioned earlier, Equations 2-7 and 2-8 are 
based on the following assumptions:  (i) the diffusion coefficient of the drug in membrane is 
constant and independent of concentration, (ii) the membrane initially is completely free of 
any drug molecules, (iii) The drug concentration at the donor side         is constant, and 
(iv) The concentration at the receptor side is kept at sink condition      .  
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2.8.2 Mass Balance Method 
   For systems in which finite conditions hold at both source and receptor side of the 
membrane, there is an alternative method for the determination of permeability coefficient. 
This method is in fact based on mass balance. The concentrations at the donor and receptor 
sides of the membrane vary with time, and applying mass balance for the permeant at both 
sides of the membrane  
                                                        
where    is the volume of the donor side,    is the volume of the receptor side and    is the 
initial concentration of the drug in the donor. As mentioned above, if the system has finite 
donor/receptor conditions, the drug concentrations at both sides of the membrane change 
with time. Further, the rate of drug permeation through the membrane is given by 
                





                              
Integrating Equation 2-11 from     to     and rearranging the equation we will have 



















This equation is widely used in the literature using a setup with equal volumes of donor and 
receptor (i.e.      ), namely the Franz Diffusion Cell.  Equation 2-12 can be rewritten as 
      











                    
where    is the total volume of the donor and the receptor compartment,             and 
          is the total initial amount of the drug at donor side. The permeability coefficient 
  can be calculated by plotting the logarithmic term of Equation 2-11 versus time,   which 
gives a straight line. The permeability can be determined from the slope of this straight line. 
The mass balance method is a more general form for determination of permeability 
coefficient. This method is also based on some assumptions such as (i) the amount of drug 
molecules within membrane is negligible, and (ii) the drug molecules is received in the 
receptor instantly as it leaves the donor compartment. In other words, membrane should be 
thin enough so that the time required to establish a steady concentration gradient across the 
membrane neglected (Chen et al., 2010; Tavelin et al., 2002; Jin and Song, 2006).  
   Chen et al., (2010) investigated both methods (i.e. time-lag and mass balance) for 
determination of intrinsic permeation parameters. By examining the assumptions underlying 
both methods, they attempt to show that a violation of those assumptions will lead to a 
significant error in determination of permeation parameters. They pointed out that the time 
lag is neither the time that the drug molecules take to pass through membrane nor the time to 
reach steady state as misperceived by other researchers. It is also stressed that the permeation 
experiments should be conducted for a sufficient long time, because the time lag is calculated 
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by extrapolating the steady-state permeation data, which occurs in theory after three times of 
time-lag. Otherwise at a shorter time of permeation test, the diffusivity coefficient might be 
underestimated. Chen et al., (2010) also clarified that for calculation of permeability 
coefficient using the mass balance method, the data at the early stage of permeation (which 
are affected by transient permeation significantly), must be excluded. Otherwise the 
permeability coefficient would be underestimated. Figure 2-5 shows how the slope of the 
logarithmic term in the Equation 2-13 changes with time at transient permeation stage. 
 
Figure ‎2-3 Illustration of underestimation in permeability calculated on the basis of the conventional 
mass balance method (Chen et al., 2010) 
 
In view of what discussed the above, they proposed an improved approach for determination 
of intrinsic permeability and diffusivity relevant to controlled release by combining the two 
methods and taking advantages of the complementary characteristics of the time-lag and the 
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mass balance techniques. Basically the short-time permeation data are analyzed using the 
time-lag method, and the long-term permeation data are evaluated with the mass balance 
method. First, one needs to determine an upper limit of time beyond which the concentration 
variation is no longer valid for time-lag method which requires infinite source and sink 
conditions. A plot of Q vs. t should be constructed excluding the long term permeation data. 
An upper limit η must be assigned below which a small change in trans-membrane 
concentration is acceptable to relax the assumptions underlying the time-lag method: 
            
     
     
                   
 Combining Equation 2-14 with Equation 2-10 gives 
                                                  
where     
  
  
   is the equilibrium concentration that will be reached at an infinite time. 
A series of η values (e.g., 2%, 5%, 10%) may be set to define an upper limit of    by 
Equation 2-15.  
  The next step in the evaluation of permeability coefficient from the long time permeation 
data is based on the time-lag obtained from the short term permeation data. An onset point 
should be determined at which the impact of transient permeation at early stage no longer 
affects the validity of the mass balance analysis. The effect of transient permeation is 
considered to be vanished after more than three times of time-lag        . The mass 
balance for the drug across the membrane after         yields: 
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where   and   are two parameters describing the onset point concentrations. Integrating  
Equation 2-11 from      to     will give 




      










                 
Based on data points from     to     , Equation 2-17 can be rewritten as 
         
       










                             
By setting a proper reference point and plotting the logarithmic term in Equation 2-18 versus 





2.8.3 Sorption and Desorption Kinetics 
Another method for determination of diffusivity and permeability coefficients is based on the 
sorption and desorption kinetics of the drug molecules through membrane sheets. Assuming 
that diffusion coefficient of drug through membrane is constant and independent of drug 
concentration, the amount of drug sorbed in the membrane    at time   is given by (Crank 
and Park 1968): 
  
  
   





             
  
    
 
   
             
where    is the equilibrium uptake after infinite time      . The sorption rate is 
considered to be controlled by diffusion and the diffusion coefficient   is assumed to be 
constant. Another underlying assumption is that the membrane thickness does not change 
during sorption or desorption. Equation 2-19 is also valid for desorption of drug from a 




  for initial gradient of    against the 
  
 
  .  Equation 2-19 is based on the 
assumption that the concentration of the drug is constant at the surface of the membrane. If, 
however, only a finite amount of drug is present initially, the concentration of drug will fall 
substantially during the sorption process as drug enters the membrane and Equation 2-19 will 
no longer be valid. In this case the drug uptake in the membrane should be determined from 
the concentration change of the drug solution. The appropriate equation expressing the total 
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amount of drug    in the membrane at time t as a fraction of    is developed by Crank 
(1975): 
     
  
  
    
       
         
      
     
 
   
            
where the   ’s‎ are‎ the‎ non-zero positive roots of            and   is the ratio of the 
volumes of drug solutions and the membrane. 
2.8.4 Partition Coefficient 
  In definition, a partition coefficient is the ratio of concentrations of a solute in two 
immiscible solvents at equilibrium and can be related to dimensionless forms of Henry’s‎
law constant (see Equation 2-21). The partition coefficient in other words is a measure of 
differential solubility of the solute in two immiscible solvents. A partition coefficient can 
also be used when one or both solvents are in a solid phase (Leo et al., 1971).  
                                 
  
  
                                        
where     is the concentration of solute in the solvent II,    is the concentration of solute in 
the solvent I, and   is‎the‎Henry’s‎law‎constant.‎ 
   The partition coefficient of drugs in a membrane can be determined by solute uptake 
experiments (Chen et al., 2010). The membrane sheet is swollen in the drug solution, and 
after equilibrium, the concentration of the solution (C1) reaches a constant value. Then by 
performing the desorption process with same membrane, taken out from the drug solution of 
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known volume (V) and desorption of drug in a solution free of drug with the same volume 
occurs till the concentration of drug released in the solution reaches a constant value (C2) 
after equilibrium. The partition coefficient of drug Kd is given by 
         
   
         
                    
 
where VP refers to the volume of the swollen membrane.  
Using Equation 2-9 the permeation coefficient is obtained by diffusivity and partition 
coefficients determined by sorption/desorption method. 




Chapter 3   Experimental 
3.1 Materials 
3.1.1 Model Drugs 
Ciprofloxacin hydrochloride, (+)-cis-diltiazem hydrochloride, and 5-nitro-2-furaldehyde, 
semicarbazone (Nitrofurazon) were chosen to be used in this work as model drugs to test the 
controlled released system.  Diltiazem hydrochloride and nitrofurazon were purchased from 
Sigma-Aldrich Co. Ltd., and used as received. Ciprofloxacin hydrochloride was obtained by 
reacting ciprofloxacin (purchased from Fluka BioChemica Co. Ltd.) with excess hydrogen 
chloride (molar ratio 1:10) at room temperature. Both ciprofloxacin and hydrogen chloride 
solution (2.0 M in diethyl ether) were supplied by Sigma-Aldrich. The reaction product was a 
light yellow suspension, which was filtered and then washed extensively with anhydrous 
diethyl ether to remove excess hydrogen chloride. After drying in air, the purified 
ciprofloxacin hydrochloride was an off-white powder. Figure 3-1 shows the chemical 
structure of model drugs. 
 
Figure ‎3-1 Molecular Structure of 1. Ciprofloxacin-HCl, 2. Diltiazem-HCl, 3. Nitrofurazon 
1 2 3 
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Ciprofloxacin hydrochloride and diltiazem hydrochloride are water soluble, whereas 
nitrofurazon is partially soluble in water. To prepare drug solutions, ciprofloxacin –HCl and 
diltiazem-HCl were dissolved in deionized water. In order to dissolve nitrofurazon 
completely in deionized water, a 5 wt% β-cyclodextrin dissolved in deionized water is 
prepared‎and‎heated‎to‎40ᵒC.‎Nitrofurazon is dissolved completely in this solution. Aqueous 
nitrofurazon solutions in 5 wt% β-cyclodextrin were prepared. The drug concentration used 
in this study was in the range of 100-400 ppm.  
3.1.2 Chitosan 
Chitosan with a deacetylation degree of 99% and a molecular weight of 100 kDa, were 
supplied from Kyowa Technos, Chiba, Japan. It was dissolved in 2 wt% aqueous acetic acid 
solutions to form 1wt% chitosan solution. Then the chitosan solution was filtered to remove 
undissolved particles and impurities. This solution is preserved in bottle at room temperature 
for further use in membrane casting. 
3.1.3 Sericin 
Sericin was extracted from silk worm Bombyx mori cocoons. To facilitate the extraction, the 
cocoons were cut into small pieces, washed thoroughly in de-ionized water and kept in water 
for 4 hours. In order to obtain the fraction of sericin proteins having relatively large 
molecular weights, the extraction was carried out in a two step process. In the first step, the 
cocoons were transferred into warm de-ionized water at 40 °C for 2 hours. During this 
period, small molecular-sized sericin proteins were dissolved in water. The aqueous solution 
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was discarded and cocoons were subjected to the second step of extraction to obtain the high 
molecular weight sericin. In this step the cocoons were transferred to boiling water for 2 
hours. After filtration and partial evaporation at about 80 °C, the thick sericin solution turned 
into a gel upon cooling. The percentage of sericin present in the gel was estimated by drying 
a known amount of gel to a constant weight. The percentage of sericin in the gel varied 
between 8.8-12 % from batch to batch. The sericin gel was kept in refrigerator for further 
use.  
3.2 Chitosan/Sericin Blend Membrane Preparation 
  Initially, it was tried to prepare the only sericin based film and sericin/chitosan based film 
using low molecular weight sericin. The dried films were treated with 5% NaOH aqueous 
solution. The membranes obtained from pure sericin were glassy and brittle that were not 
possible to peel off the plate. Also low molecular weight sericin and chitosan blend 
membranes were gel like and easily broke away while holding. Therefore sericin cannot be 
used to form films alone low molecular weight sericin also does not turn to a gel by cooling, 
neither can make a film as blended by chitosan.  
 Homogeneous chitosan/sericin membranes were prepared by the solution casting technique. 
The sericin-chitosan blend membranes were prepared by slowly warming up the sericin gel 
in the presence of small amount of water to turn it into a clear liquid, which was then blended 
with 1 wt % solution of chitosan in 2% (v/v) aqueous acetic acid solution. After a thorough 
mixing, a pre-determined amount of crosslinking agent glutaraldehyde (GA) was added and 
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mixed thoroughly for 30 minutes. The membranes were prepared by casting about 25 ml of 
the polymer solution in plastic Petri dishes, which were dried at room temperature for 24 
hours followed by heat treatment at 60 °C for 1 h. The blend compositions are given in Table 
3-1. After drying, the membranes were treated with 5 %wt NaOH dissolved in a 1:1 ethanol 
aqueous solution for 24h to convert the cationic amine groups of chitosan (-NH3
+
) to the free 
amine form (-NH2). The membranes were rinsed thoroughly with deionized water prior to 
use.  The resulting membranes were dense and homogeneous, and thus the drug release was 
by diffusion in the membrane, and not by diffusive or convective transport in pores as in a 
porous matrix. However, not all the membranes were suitable for controlled release studies 
because the membranes with higher degrees of crosslinkings were easily cracked when 
placed in the membrane holder. It was realized that the high percentage of GA (i.e. 2.5-4.5%) 
is responsible for the membrane cracking while holding. In order to save the sericin, 
membrane were casted by using only chitosan and GA in different percentages to get a 
suitable membrane. It was found that the chitosan membranes prepared using 0.08- 0.4% of 
GA were quite good in all respects.  So the next batch of sericin/chitosan based membranes 
were prepared by using the 0.08-0.4% of GA. The sericin/chitosan based membranes with 
GA in 0.08-0.4% are quite stable membranes and would be a good starting point to test these 
membranes for controlled drug release studies and to study the effect of GA on the 




Table ‎3-1 Compositions of sericin/chitosan blend membranes 





1 1:10 4.5 After drying, the membranes were easily peeled off 
in 5% NaOH aqueous ethanol solution. The 
membranes were cracked while placing in the 
membrane holder due to high degree of 
crosslinking.    
2 1:3 3.7 
3 1:2 3.3 
4 1:1 2.5 
5 1:4 0.4 After drying, the membranes were easily peeled off 
in 5% NaOH aqueous ethanol solution. The thin 
membranes can be hold easily without breaking. 
All these membranes seem to be suitable for the 
application of controlled drug release. 
6 1:4 0.24 
7 1:4 0.16 
8 1:4 0.08 
Glutaraldehyde content (GA%)  is with respect to the mass of the sericin/chitosan blend. 
The sericin/chitosan membranes with blend ratio of 1:4 have been found to work well at 
varying concentration of crosslinking agent in terms of membrane stability and integrity. In 
all the permeation and sorption/desorption experiment, membranes with this composition 
were used. 
3.3  Permeation experiments 
The experimental apparatus for permeation experiments is shown schematically in Figure 3-
2. It was comprised of a source compartment of 100 ml capacity and a receiving 
compartment of 2,500 ml capacity. The membrane, which had been stored in deionized 
water, was mounted horizontally at the bottom of the source compartment, which was 
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suspended on top of the receiving compartment. Then the receiving compartment was filled 
with 2,000 ml of deionized water, and the source compartment was lowered to be partially 
immersed in water. At time zero, the source compartment was filled with 80 ml of the drug 
solution at a predetermined concentration (ranging from 0.1 to 0.4 mg/ml) so that permeation 
started to occur. Vigorous agitations were provided mechanically in both compartments to 
eliminate the boundary layer effect, and this was confirmed by the fact that the measured 
permeability and diffusivity remained constant when membranes with different thickness 
were used to study the boundary layer resistance effect. The concentration of the drug in the 
receptor side during the course of permeation was measured using a Shimadzu UV–Vis 
spectrophotometer. The effective area of the membrane for permeation was 12 cm
2
.The 
thicknesses of the membranes were determined by a digital micrometer at several spots and 











3.4 Sorption and Desorption  
  The sorption experiments were conducted by immersing pre-swollen membrane samples in 
deionized water, then into 50 ml aqueous solutions of drugs at various known concentrations 
maintained at room temperature. The concentration of drug compounds in the solutions 
varied in the range of 100 to 400 ppm. The equilibrium sorption uptake was determined after 
the membrane sample was submerged in the liquid for a sufficiently long time (at least 24 h) 
and no further increase in the sorption uptake was observed. The quantity of the sorption 
uptake with time was determined from the concentration change of the drug solutions as 
measured by the spectrophotometric method. Desorption experiments were also carried out 
immediately after the swollen membrane was weighed using a digital balance. Desorption 
experiments were carried out by putting the drug-loaded membrane, in 50ml of deionized 
water. The concentration change of the drug released to the deionized water at different times 
time was monitored spectrophotometricly.  
3.4.1 Determination of partition coefficient  
The partition coefficients of drugs in the membranes were also determined by 
sorption/desorption experiments, where the concentration of the drug solution at equilibrium 
in sorption C1, and the desorbed concentration of drug in the deionized water after reaching 
the equilibrium C2 were determined spectrophotometricly. The partition coefficients Kd of 




3.5 Degree of Swelling  
The degrees of swelling (   ) of the membrane drug solutions were determined at 22 °C 
from mass uptake using the following equation: 
    
   
  
                        
where Wd is the weight of a dry membrane sample and Wsw the weight of the swollen 
membrane. 
3.6 Effect of boundary layer 
To study whether there was a boundary layer resistance in the permeation system, the release 
of ciprofloxacin hydrochloride through the membrane, was determined using membranes of 




Chapter 4  Results and Discussion 
4.1 Effect of boundary layer  








   
 




 is the amount of solute that permeates through the membrane in unit time and    is 
the concentration difference between the donor and receptor chamber. At steady state of 
permeation, the permeation flux (  ) is inversely proportional to the thickness of the 
membrane. However in systems where a boundary layer is not negligible on either surface of 
the membrane, the boundary layer will contribute to an additional resistance to drug 





   
                             
where    is the boundary layer resistance. It can be seen that a plot of 
 
  
  versus   will yield a 
straight line with a positive intercept on the y- axis, and the boundary layer resistance can 
thus be determined from the intercept of the straight line. 
  The permeation flux of ciprofloxacin hydrochloride through the membranes of different 
thicknesses was measured to determine whether there is boundary layer effect in the test 
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system. An initial drug concentration of 0.1 
  
  
 was used in the tests. All the membrane 
thicknesses reported in this work were the thicknesses of swollen membranes. As expected, 
the steady-state permeation flux of the drug decreases as the thickness of the membrane 




 and thickness of the membrane l, with a y-axis intercept close to the point 
of origin. This indicates the negligible effects of boundary layers on both sides of the 
membrane in the system under the experimental conditions. Therefore the diffusivity and 
permeability coefficients determined for this system are the intrinsic kinetic values for drug 
transport through the membranes.  
 
 
Figure ‎4-1 Relationship between the reciprocal of steady-state flux and membrane thickness, 
sericin/chitosan blend ratio in the membranes 1:4, amount of crosslinking agent 0.4% of sericin/chitosan 

























4.2 Swelling Degree of Membranes 
The water sorption capacity of the sericin/chitosan membranes were determined by swelling 
the sericin/chitosan membranes in water and in drug solutions with concentrations ranging 
from 100 to 400 ppm at room temperature. The degree of swelling of a membrane is 
governed by its crosslinking density, temperature, composition of the solution, and 
interaction between the solution and the membrane (Thacharodi and Rao, 1993). Swelling 
can be altered over a wide range by crosslinking and concentration of the solution. However, 
the swelling behavior of the sericin/chitosan membranes, which were crosslinked with 
glutaraldehyde in water and the drug solutions, did not vary significantly. The degrees of 
swelling of the membranes are shown in Figure 4-2. The equilibrium swelling degrees in 
water were in the range of (265-272%) which is similar to degrees of membrane swelling in 
the drug solutions, presumably due to the low concentrations of the compounds in the 
solutions. As can be seen in Figure 4-2, there is no significant change in the swelling of the 
membranes due to change in the crosslinking density. This may be because of the high 
affinity of chitosan and sericin with water molecules as both polymers have strong 
hydrophilic groups, or probably the crosslinking times (i.e. 30 min) were sufficiently long to 


























































Chen et al., (2010) have studied the swelling degree of pure chitosan membranes in 
ciprofloxacin-HCl solutions and their results also showed that the swelling degrees of the 
chitosan membranes are not affected by the change in the drug concentrations. They reported 
that the degrees of swelling of chitosan membranes was 164% which is consistent with the 
results obtained (i.e. 267% for ciprofloxacin-HCl) in view that a blend of sericin/chitosan 




4.3 Permeation Results 
4.3.1 Time-lag analysis of short-time permeation data 
A plot of the mass of drugs permeated   versus time   was constructed for the three model 
drugs with initial concentrations varying in the range of 100-400 ppm for sericin/chitosan 
blend membranes with different crosslinking densities. The concentration difference across 
the membrane is driving force for permeation, and it changes from        at beginning 
to         at time  . The long time permeation data must be excluded in accordance with 
the criteria discussed earlier, to apply Equations 2-6 and 2-7 for calculation of time-lags. An 
upper limit      was assigned to allow a relative change in the trans-membrane 
concentration within 5% to relax the assumptions of constant source concentration and zero 
sink concentration. Obviously, smaller values of η‎lead‎to‎more‎accuracy‎in‎determination‎of‎
the time lag, but on the other hand, there will be fewer data available for extrapolation (Chen 
et al., 2010). Different values of η‎have‎been‎tested‎(ranging from 5-15%) for the three drugs. 
The value of      was found to be the optimum for calculation of time-lags for the 
permeation of the three drugs.  
   The diffusion coefficients DT of ciprofloxacin hydrochloride, diltiazem hydrochloride, and 
nitrofurazon through the sericin/chitosan membrane crosslinked with different concentrations 
of glutaraldehyde at four initial concentrations of drugs were determined from the time-lag. 
Figure 4-3 shows the diffusivities so determined from the time-lag based on short-time 
permeation data. The diffusivity coefficients of ciprofloxacin hydrochloride were in the range 
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of                          cm2/s, which are well within the common range of drug 
diffusivities in various membranes. Furthermore, the diffusivity coefficients of diltiazem 
hydrochloride and nitrofurazon in the membranes were in the range of                
          and                         (cm2/s), respectively. These values also fall 
completely in the common range of diffusivities reported for different drugs in chitosan 
based membranes. The permeation of drug molecules through membranes may be explained 
by a process consisting of three steps: sorption, diffusion, and desorption. In the time-lag 
method, it is assumed that the diffusion is the rate controlling step, and the sorption and 
desorption of the drug on the surfaces of the membrane occur instantaneously. Therefore, the 
diffusivity of drug molecules in the membrane is affected by the chemical interactions 
between the drug molecules and the polymers forming the membrane, and the morphology of 
the membrane. No clear trend was observed for the influence of drug concentration on the 
permeability and diffusivity within the experimental error in the concentration ranges tested. 
This means that the underlying assumption of concentration independency of the diffusivity, 
used in the diffusivity measurements appears to be satisfactory in the experimental range 
studied. Compared to the diffusivity coefficients of two other drugs, the diffusivity of 







the drug concentrations studied. This is due to the effect of presence of β-cyclodextrin added 
in the donor and receptor medium. β-cyclodextrin may act as a penetration enhancer. The 
effects of hydrophilic cyclodextrin on drug flux through various types of artificial and 
biological membranes have been studied extensively in the literature. It has been shown that 
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cyclodextrin enhances the penetration of lipophilic drugs by increasing the drug/cyclodextrin 
complex concentration in the donor side, thereby improving the interaction of permeating 
drug and the membrane (Loftsson et al., 2007). Therefore there is a significant difference in 
the diffusivity between nitrofurazon (a hydrophobic drug) and ciprofloxacin-HCl and 
diltiazem-HCl (two hydrophilic drugs). In fact, it is the enhancing effect of cyclodextrin that 
has been used to dissolve nitrofurazon in the aqueous solution, as discussed in the 
































































































   The pseudo-steady state permeability coefficient of the drugs through the membranes can 
be determined from the slope of Q vs. t plots using the permeation data at the early 
permeation stage. As discussed previously, the permeability coefficient calculated from the 
short-term permeation data may be affected by transient permeation leading to an 
underestimation in the permeability. However it will be beneficial to calculate the 
permeability using the time-lag method in order to compare with permeability coefficient 
obtained from the long-time permeation data bases on the mass balance method. The 
permeability coefficients determined from the short-term permeation data, PT, at different 
drug concentrations are shown in Figure 4-5. It is shown that the permeabilities of 
ciprofloxacin-HCl and diltiazem-HCl in the membranes are in the range of              
         , and                            
 
  , respectively. The permeability of 
nitrofurazon which is a hydrophobic drug in the membranes is in the range of          
                 
 
   . Further, the permeabilities of the three drugs through the membranes 
are shown to be independent of their concentrations in the experimental range studied, in 
spite of the fluctuations in the permeability calculated due to experimental errors. The 
fluctuations in the permeability coefficients are much more significant for nitrofurazon. This 
might also be related to the presence of β-cyclodextrin in the drug solution at the donor 
compartment and the receptor side. Cyclodextrin is hydrophilic and has a cage structure, and 
its presence in the solution of nitrofurazon is expected to enhance the drug permeation. 
Cyclodextrins are good options to be used either for complexation or as functional carrier 
materials in drug delivery. A main characteristic of cyclodextrin is forming an inclusion 
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complex in solution which surrounds the hydrophobic substance within its cavity (Loftsson et 
al., 2007). The macrocyclic ring structure of β-cyclodextrin is presented in Figure 4-4.   This 
is probably why the hydrophobic nitrofurazon exhibited higher permeability in the 
hydrophilic membranes than the hydrophilic drugs (i.e., ciprofloxacin hydrochloride and 
diltiazem hydrochloride) in the absence of cyclodextrin.  
 
 







Figure ‎4-5 Permeability PT determined on the basis of pseudo steady state permeation using short-time 





























































































Generally speaking, crosslinking will improve the chemical stability and mechanical strength 
of a membrane. Membrane crosslinking often causes a decrease in its permeability and 
diffusivity. However, over the crosslinking agent concentrations used in this study, no clear 
trend can be observed with respect to the effect of crosslinking on diffusivity and 
permeability. A relatively low concentration of glutaraldehyde was used for membrane 
crosslinking in this study, which may have just helped the stability of the membrane but did 
not change the membrane morphology or reduce the chemical functionality of chitosan and 
sericin significantly. 
4.3.2 Long-time permeation data analysis with mass balance method 
 The impact of transient permeation is considered to have diminished after three times of the 
time-lag. Therefore, the long time        permeation data are subjected to mass balance 
analysis. Based on Equation 2-18, by selecting an appropriate reference point t0 and plotting 
F (t) =−ln [(m0−VtCR)/(m0−Vta)]  against t, a straight line will be obtained and permeability 
coefficient   can be calculated from its slope. 
   After the time-lag was obtained from the short-time permeation data, we were able to set a 
reference point       , and only the permeation data beyond this point were used to 
determine the permeability coefficient PM of the drugs using the mass balance analysis (Chen 
et al., 2010).   Using the long-time permeation data, the permeability coefficient, PM, was 
calculated from the slope of the plot of           using Equation 2-18. The results are shown 
in Figure 4-6 for the three model drugs. The PM values for ciprofloxacin-HCl and diltiazem-
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HCl were shown to be in the range of                       ,                     
       
 
    respectively. Nitrofurazon was determined to have a permeability of          
                  
 
   . In general the PM values tend to be slightly greater than the PT 
values obtained from the time-lag method and this is not unexpected because of the two 
different methods used. As discussed earlier, the effect of concentration variations on 
evaluation of PT was neglected based on pseudo steady state permeation. Therefore, there is 
an underestimation in the permeability determined using the short-time data and PM appears 
to be more realistic to measure the membrane permeability. As can be seen in Figure 4-5, a 
variation in initial concentration of the drugs has no significant effect on the PM determined. 
This is expected considering the concentration independency of diffusivity and permeability 
coefficients of the permeation system. There is a more significant fluctuation in the PM 
values for nitrofurazon when compared to the PM values for ciprofloxacin-HCl and diltiazem-
HCl. This can be explained by the presence of β-cyclodextrin in nitrofurazon permeation 
system. The concentration of crosslinking agent also did not show a clear trend in PM in the 
test range studied here. Membrane crosslinking generally leads to a decrease in permeability, 
diffusivity and solubility of the drug in the membrane: (i) the crosslinked sites in the 
membrane polymer are more impermeable for the diffusion process, and the penetrating drug 
molecules have to migrate around the barrier sites which lengthen the path of diffusion 
relative to nominal dimension of the membrane, (ii) The chemical modification of the 
membrane matrix at crosslinking points changes the interaction between the membrane 
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polymer and the drugs (Thacharodi and Rao, 1993). The fluctuation in PM values but no 
specific trend with respect to concentration of crosslinking agent may be attributed to the low 
concentrations of glutaraldehyde used in this study which helped improving the stability of 



































































































   Since diffusivity and permeability coefficients DT, PT and PM found to be independent of 
the drug concentration in the concentration ranges studied in this work, the average values of 
these permeation parameters are calculated for each drug penetrant through the 
sericin/chitosan membranes at different crosslinking degrees for better comparison. The 
results are summarized in Table 4-1. 
Table ‎4-1 Average diffusivity and permeability of drugs in the sericin/chitosan membrane 
  
Drug GA % 
DT PT PM 
x 109(cm2/s) X 108 (cm2/s) X 108 (cm2/s) 
Ciprofloxacin-HCl 
0.40 2.0 22.4 26.6 
0.24 2.3 20.6 28.9 
0.16 2.2 18.1 23.5 
0.08 2.6 17.7 24.9 
Diltiazem-HCl 
0.40 2.6 5.1 5.1 
0.24 2.5 5.1 5.1 
0.16 2.6 5.0 5.2 
0.08 2.5 4.9 5.0 
Nitrofurazon 
0.40 55.2 151.1 137.1 
0.24 74.2 190.0 168.8 
0.16 115.1 152.7 130.7 
0.08 104.3 134.3 136.2 
DT: diffusivity determined from time lag using short-time permeation data  
PT: permeability determined from pseudo steady state stage using short-time permeation data  




4.4 Results from Sorption and Desorption Studies 
The sorption and desorption studies provide information about sorption isotherms as well as 
the kinetics of sorption and desorption of drug permeation in the sericin/chitosan membranes. 
The amount of drug sorbed by the membrane at a given instant    was determined from 
concentration change in the drug solution measured by the UV-Vis spectrophotometer. 
Figures 4-7 and 4-8 show the typical 
  
  
         plots for the sorption and desorption of 
ciprofloxacin-HCl with an initial concentration of 100 ppm in a sericin/chitosan membrane. 
The membrane composition was 1:4 sericin/chitosan by weight, crosslinked by 0.40 wt% 
glutaraldehyde with respect to sericin/chitosan blend. Similar results are shown in Appendix 
for sorption and desorption of other drugs through the sericin/chitosan membranes with 
different degrees of crosslinking. The diffusion coefficients were evaluated by data fitting to 
Equation 2-20 with the assistance of Polymath 6.1. The diffusivity so determined from 




Figure ‎4-7 Sorption kinetics of ciprofloxacin-HCl. Initial drug concentration 100 ppm. Sericin/chitosan 
blend ratio 1:4; GA amount 0.40% wt with respect to the sericin/chitosan blend ratio 
 
Figure ‎4-8 Desorption kinetics of ciprofloxacin-HCl. Initial drug concentration 100 ppm. Sericin/chitosan 
blend ratio 1:4; GA amount 0.40% wt with respect to the sericin/chitosan blend ratio 
   Figures 4-9 and 4-10 show the diffusivity of the three model drugs in the membranes as 
determined from sorption and desorption kinetics. It can be seen that the diffusion coefficient 
determined by the sorption and desorption experiments tend to be independent of the initial 
drug concentrations. Equation 2-20 for calculation of DS and DD, is based on the assumption 





























in agreement with the assumption.  The average diffusivities of the drugs in the membranes 
with different degrees of crosslinking are summarized in Table 4-2. The average diffusivities 
of the drugs, DS and DD, tend to decrease as the concentration of crosslinking agent increases. 
These results are in agreement with the theory; however, as discussed before, no specific 
trends in their permeabilities were observed with regard to the crosslinking degree of the 
membranes. Nonetheless the differences in the diffusivities calculated from permeation and 
sorption/desorption experiments are considered to be acceptable, in view of the different 
experimental techniques used in this work, for the purpose of comparison of the membrane 
diffusivity and permeability. 
Table ‎4-2 Average diffusivity coefficients of drugs calculated from sorption and desorption kinetics  










Ciprofloxacin-HCl 0.40 7.6±2.0 19.7±14.1 
0.24 7.2±2.0 35.0±14.1 
0.16 5.1±2.0 40.4±14.1 
0.08 3.2±2.0 46.9±14.1 
Diltiazem-HCl 0.40 5.9±1.8 18.6±5.3 
0.24 6.2±1.8 21.7±5.3 
0.16 7.2±1.8 11.9±5.3 
0.08 10.1±1.8 23.7±5.3 
Nitrofurazon 0.40 15.7±1.9 11.0±4.5 
0.24 15.2±1.9 16.3±4.5 
0.16 14.7±1.9 19.6±4.5 
0.08 18.2±1.9 19.7±4.5 
DS: diffusivity determined from sorption experimental data 




Figure ‎4-9 Diffusivity DS determined from sorption kinetics; sericin/chitosan blend ratio 1:4; GA wt% 




























































































Figure ‎4-10 Diffusivity DD determined from sorption kinetics; sericin/chitosan blend ratio 1:4; GA wt% 




























































































4.4.1 . Partition Coefficient 
The permeation of drugs in the membranes can be described by solution-diffusion model. 
That is, the drug dissolves in the membrane and diffuses through membrane, and then 
desorbs from the membrane. The partition coefficients Kd for ciprofloxacin-HCl, diltiazem-
HCl, and nitrofurazon were determined from sorption/desorption experiments using Equation 
2-22. The partition coefficients for ciprofloxacin-HCl, diltiazem-HCl and nitrofurazon were 
found to be (0.9±0.21) and (25±0.12), and (26±0.31) respectively. As shown in Figure 4-11, 
the partition coefficients Kd of the drugs in the sericin/chitosan membranes is independent of 
the drug concentrations. Also, the partition coefficients are not affected by the degree of 
crosslinking in the membranes. Thacharodi and Rao (1993) have shown that transport of 
highly water soluble drugs such as propranolol hydrochloride through a chitosan membrane 
was by the pore mechanism where the drugs are transported through membranes 
microchannels, whereas the hydrophobic drugs or less water soluble drugs will be 
transported through the chitosan membranes by partition mechanism significantly. The Kd 
obtained for ciprofloxacin-HCl in the sericin/chitosan membrane was less than unity (Kd ≤‎1),‎
and the transport of this drug through the membrane appears to be influenced by 
microchannel transport mechanism. On the other hand, the transport of diltiazem-HCl and 






Figure ‎4-11 Partition coefficient Kd determined from sorption/desorption experiments; sericin/chitosan 






















































































Chapter 5  Conclusions 
   In this work new membranes were prepared by blending sericin and chitosan for controlled 
release of drugs. The chitosan/sericin membranes were prepared by a solution casting 
technique, and the membranes were quite stable, homogeneous and transparent. These 
membranes were tested for controlled release of three model drugs including two hydrophilic 
(ciprofloxacin hydrochloride and diltiazem hydrochloride) and a hydrophobic (nitrofurazon). 
The intrinsic property parameters such as diffusivity, permeability and partition coefficients 
of the three drugs in the membranes were evaluated using permeation experiments and 
sorption/desorption tests. The setup for permeation experiments was found to have negligible 
boundary layer resistance. 
   The swelling degrees of the membranes with different degrees of crosslinking have been 
measured. The swelling degrees of the membranes were shown to be independent of drug 
concentrations and the degree of crosslinking over the experimental range tested in this work.  
Similarly, the drug concentration and membrane crosslinking did not exhibit significant 
effects on the diffusivity, permeability and partition coefficients of the three model drugs in 
the membranes. The diffusivity coefficients of the drugs in the membranes, were shown to be 













/s). This is quite acceptable for controlled release applications when compared to the 
previous work.  
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   The partition coefficients of the drugs were determined by sorption/desorption experiments. 
They were found to be (0.9±0.21) for ciprofloxacin-HCl, (25±0.12) for diltiazem-HCl and 
(26±0.31) for nitrofurazon, respectively. The permeation of ciprofloxacin-HCl, which is 
highly water soluble and has a strong interaction with amine groups in chitosan and sericin, 
appear to follow microchannel transport mechanism, while transport of less hydrophilic 
diltiazem-HCl and hydrophobic nitrofurazon appeared to be governed by the partition 
mechanism. 
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Chapter 6  Recommendations 
  Based on results obtained in this work, the following are recommended that may provide a 
further insight into controlled release of drugs using sericin/chitosan blend membranes: 
This work deals mainly with the controlled release of ciprofloxacin-HCl, diltiazem-HCl and 
nitrofurazon using the newly developed chitosan/sericin blend membranes, and the 
diffusivity, permeability and partition coefficients of the drugs as well as swelling degree of 
the membranes were determined. In addition to the three model drugs investigated, these 
membranes should be tested with other different water soluble and insoluble drugs to gain 
further information on the general applicability of the membranes for controlled release. It is 
therefore recommended testing the membranes with other drugs, and if necessary modifying 
the composition and membrane crosslinking conditions. Further, the sericin/chitosan blend 
membrane may also be modified to achieve suitable structure for controlled release by matrix 
diffusion, and the following is recommended: 
 Preparation of drug loaded films and evaluation of drug release profile and kinetics. 
 Characterization of the membrane loaded by drugs and structural analysis in order to 
better understand the drug/membrane interactions 
 Study of the effects of composition of drug loaded films and crosslinking degree as 
well as drug loading on the release profile 
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Appendix A : Sample calculations 
7.1.1. A.1. Permeation experiments 
Determination of diffusivity and permeability using time-lag and mass balance method 
 
Figure ‎6-1 The permeated ciprofloxacin-HCl Q versus time through sericin/chitosan membrane, Initial 
drug concentration 400 ppm, GA%: 0.08, membrane thickness 76µm, η=5% 
 
                 
Membrane thickness   = 76 µm               Membrane Area= 12 cm2 
  
    
 




   
  
  
                            
       
       
             
 
    
y = 0.0066x - 0.4061 




























    
        
   
  
             
        
 
    
      
              
 
    
                        
 
Plotting F (t) =−ln [(m0−VtCR)/(m0−Vta)]  versus t  
 
 
Figure ‎6-2 long time permeation data, F(t) vs. t, (t0 >3 Ɵ) sericin/chitosan membrane, Initial drug 
concentration 400 ppm, GA%: 0.08, membrane thickness 76µm 
 
    











   
   








                  
 






            
 
     
  
y = 0.0003x - 0.0513 














7.1.2. A.2 Sorption and Desorption experiments 




    
       
         
      
     
 
   
 
 
          
 
 
Table ‎6-1 Non-zero positive roots of tan (qn)=αqn  are illustrated in table below 
qn αqn tan(qn) 
0 0 0 
1.54491064 38.622766 38.622762 
4.7038856 117.5971394 117.5971393 
7.84888541 196.2221353 196.2221355 
10.9919353 274.79838180 274.7983818 
14.1343370 353.358424 353.3584241 
17.2764443 431.9111077 431.9111077 
20.4183932 510.4598308 510.4598325 
23.5602471 589.0061782 589.0061782 
26.7020395 667.5509886 667.5509886 
29.8437899 746.0947474 746.0947474 










    
   
    
Membrane thickness   = 76 µm               Membrane Area= 12 cm2 
POLYMATH Report Ciprofloxacin –HCl desorption 400 ppm GA 0.1   
Nonlinear Regression (L-M) 14-Nov-2011 
 
Model: M = 1-0.85655*exp(-2.386749*A*t)-0.09383*exp(-22.12186*A*t)-0.0337407*exp(-
61.60500*A*t)-0.01721*exp(-120.822641*A*t)-0.010409*exp(-199.7795*A*t)-0.0069678*exp(-
298.4755*A*t)-0.00498858*exp(-416.91078*A*t)-0.0037469*exp(-555.085245*A*t)  
Variable  Initial guess  Value  95% confidence  
A  5.0E-08  0.1154553  0.0112184  
 
Nonlinear regression settings  
Max # iterations = 64  
 
Precision  
R^2  0.9754133  
R^2adj  0.9754133  
Rmsd  0.0066787  
Variance  0.001518  
 
General  
Sample size  33  
Model vars  1  
Indep vars  1  
Iterations  12  
 
Source data points and calculated data points  
 
t  M  M calc  Delta M  
1  0  0  -0.027443  0.027443  
2  0.5  0.176056084  0.2265525  -0.0504965  
3  1  0.306050982  0.3424306  -0.0363796  
4  2  0.458564683  0.5058022  -0.0472376  
5  3  0.644856585  0.625219  0.0196376  
6  4  0.757450592  0.7155171  0.0419335  
 
 80 
7  5  0.862879526  0.7840386  0.0788409  
8  6  0.870044599  0.8360543  0.0339903  
9  7  0.884374745  0.8755415  0.0088333  
10  8  0.895634146  0.905518  -0.0098838  
11  9  0.903822801  0.9282745  -0.0244517  
12  10  0.910987874  0.9455499  -0.0345621  
13  12  0.918152947  0.9686204  -0.0504674  
14  14  0.924294439  0.9819159  -0.0576215  
15  16  0.931459512  0.9895781  -0.0581186  
16  18  0.936577421  0.9939939  -0.0574164  
17  20  0.938624585  0.9965387  -0.0579141  
18  25  0.944766076  0.9991273  -0.0543612  
19  30  0.952954731  0.99978  -0.0468252  
20  35  0.957049059  0.9999445  -0.0428955  
21  40  0.960119805  0.999986  -0.0398662  
22  45  0.962166968  0.9999965  -0.0378295  
23  50  0.964214132  0.9999991  -0.035785  
24  55  0.967284878  0.9999998  -0.0327149  
25  60  0.970355623  0.9999999  -0.0296443  
26  80  0.977520697  1.  -0.0224793  
27  90  0.981615024  1.  -0.018385  
 28  100  0.985709352  1.  -0.0142906  
29  120  0.994921589  1.  -0.0050784  
30  180  0.996968752  1.  -0.0030312  
31  240  0.996968752  1.  -0.0030312  
32  300  0.997992334  1.  -0.0020077  
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Appendix B: Experimental Data 
7.1.3. Permeation experiments 
Ciprofloxacin-HCl 
 
Figure ‎6-3 short-time permeation data, ciprofloxacin-HCl : 400 ppm, sericin/chitosan 1:4, GA: 0.08%  
 
 
Figure ‎6-4 long-time permeation data. Ciprofloxacin-HCl : 400 ppm, sericin/chitosan 1:4, GA: 0.08% 
y = 0.0066x - 0.4061 























y = 0.0003x - 0.0513 















Figure ‎6-5 short-time permeation data, ciprofloxacin-HCl : 300 ppm, sericin/chitosan 1:4, GA: 0.08% 
 
 
Figure ‎6-6 long-time permeation data. Ciprofloxacin-HCl : 300 ppm, sericin/chitosan 1:4, GA: 0.08% 
y = 0.0052x - 0.3226 













y = 0.0003x - 0.0582 

















Figure ‎6-8 long-time permeation data Ciprofloxacin-HCl : 200 ppm, sericin/chitosan 1:4, GA: 0.08% 
y = 0.0031x - 0.2055 














y = 0.0004x - 0.0646 


















Figure ‎6-10 long-time permeation data Ciprofloxacin-HCl : 100 ppm, sericin/chitosan 1:4, GA: 0.08% 
 
y = 0.0017x - 0.1022 













y = 0.0002x - 0.0398 


















Figure ‎6-12 long-time permeation data Ciprofloxacin-HCl : 400 ppm, sericin/chitosan 1:4, GA: 0.16% 
 
y = 0.0073x - 0.5512 














y = 0.0003x - 0.0684 














Figure ‎6-13 short-time permeation data Ciprofloxacin-HCl : 300 ppm, sericin/chitosan 1:4, GA: 0.16% 
 
 
Figure ‎6-14 long-time permeation data Ciprofloxacin-HCl : 300 ppm, sericin/chitosan 1:4, GA: 0.16% 
 
y = 0.0054x - 0.4414 













y = 0.0003x - 0.0591 


















Figure ‎6-16 long-time permeation data Ciprofloxacin-HCl : 200 ppm, sericin/chitosan 1:4, GA: 0.16% 
 
y = 0.0035x - 0.2635 














y = 0.0003x - 0.0647 



































y = 0.0002x - 0.0394 














Figure ‎6-19 short-time permeation data Ciprofloxacin-HCl : 400 ppm, sericin/chitosan 1:4, GA: 0.24% 
 
 
Figure ‎6-20 long-time permeation data Ciprofloxacin-HCl : 400 ppm, sericin/chitosan 1:4, GA: 0.24% 
 
y = 0.0089x - 0.5013 















y = 0.0004x - 0.0719 


















Figure ‎6-22 long-time permeation data Ciprofloxacin-HCl : 300 ppm, sericin/chitosan 1:4, GA: 0.24% 
 
y = 0.007x - 0.4697 













y = 0.0003x - 0.0669 














Figure ‎6-23 short-time permeation data Ciprofloxacin-HCl : 200 ppm, sericin/chitosan 1:4, GA: 0.24% 
 
 
Figure ‎6-24 long-time permeation data Ciprofloxacin-HCl : 200 ppm, sericin/chitosan 1:4, GA: 0.24% 
 
y = 0.0039x - 0.2608 













y = 0.0004x - 0.0836 














Figure ‎6-25 short-time permeation data Ciprofloxacin-HCl : 100 ppm, sericin/chitosan 1:4, GA: 0.24% 
 
 




y = 0.0022x - 0.1425 














y = 0.0004x - 0.0951 















Figure ‎6-27 short-time permeation data Ciprofloxacin-HCl : 400 ppm, sericin/chitosan 1:4, GA: 0.40% 
 
 













y = 0.0091x - 0.6226 
R2 = 0.9997 
y = 0.0004x - 0.072 














Figure ‎6-29 short-time permeation data Ciprofloxacin-HCl : 300 ppm, sericin/chitosan 1:4, GA: 0.40% 
 













y = 0.0067 - 0.4592 
          R2 = 0.9994 
y = 0.0003x - 0.0593 














Figure ‎6-31 short-time permeation data Ciprofloxacin-HCl : 200 ppm, sericin/chitosan 1:4, GA: 0.40% 
 















y = 0.0043 - 0.2883 
R2 = 0.9998 
y = 0.0004x - 0.0832 














Figure ‎6-33 short-time permeation data Ciprofloxacin-HCl : 100 ppm, sericin/chitosan 1:4, GA: 0.40% 
 
 
Figure ‎6-34 long-time permeation data Ciprofloxacin-HCl : 100 ppm, sericin/chitosan 1:4, GA: 0.40% 
 
 
y = 0.0033x - 0.218 













y = 0.00036x - 0.07425 




























100 76 ±5 60 2.67E-09 1.81E-07 1.62E-07 
200 76 ± 5 66 2.43E-09 1.69E-07 3.25E-07 
300 76 ± 5 62 2.59E-09 1.79E-07 2.65E-07 
400 76 ± 5 61 2.61E-09 1.80E-07 2.44E-07 
0.16 
100 77 ± 6 74 2.23E-09 1.51E-07 1.64E-07 
200 77 ± 6 75 2.19E-09 1.93E-07 2.47E-07 
300 77 ± 6 74 2.24E-09 1.89E-07 2.47E-07 
400 77 ± 6 76 2.18E-09 1.91E-07 2.80E-07 
0.24 
100 72 ± 4 65 2.22E-09 2.09E-07 3.08E-07 
200 72 ± 4 67 2.15E-09 1.89E-07 3.08E-07 
300 72 ± 4 67 2.15E-09 2.10E-07 2.31E-07 
400 72 ± 4 56 2.57E-09 2.18E-07 3.08E-07 
0.40 
100 70 ± 5 66 2.06E-09 2.48E-07 2.69E-07 
200 70 ± 5 67 2.03E-09 2.35E-07 2.99E-07 
300 70 ± 5 69 1.97E-09 1.95E-07 2.24E-07 





 Diltiazem hydrochloride 
 
Figure ‎6-35 short-time permeation data, diltiazem-HCl: 400 ppm, sericin/chitosan 1:4, GA: 0.08% 
 
 
Figure ‎6-36 long-time permeation data. diltiazem -HCl : 400 ppm, sericin/chitosan 1:4, GA: 0.08% 
y = 0.0018x - 0.1458 























y = 0.0002x - 0.0618 















Figure ‎6-37 short-time permeation data, diltiazem -HCl : 300 ppm, sericin/chitosan 1:4, GA: 0.08% 
 
 
Figure ‎6-38 long-time permeation data diltiazem -HCl : 300 ppm, sericin/chitosan 1:4, GA: 0.08% 
y = 0.0013x - 0.102 













y = 0.0002x - 0.0477 

















Figure ‎6-40 long-time permeation data diltiazem -HCl : 200 ppm, sericin/chitosan 1:4, GA: 0.08% 
y = 0.00081x - 0. 0633 














y = 0.0001x - 0.0766 


















Figure ‎6-42 long-time permeation data diltiazem -HCl : 100 ppm, sericin/chitosan 1:4, GA: 0.08% 
 
y = 0.0004x - 0. 0299 













y = 0.0001x - 0.068 


















Figure ‎6-44 long-time permeation data diltiazem -HCl : 400 ppm, sericin/chitosan 1:4, GA: 0.16% 
 
y = 0.0018x - 0.1331 














y = 0.00011x - 0.01644 














Figure ‎6-45 short-time permeation data diltiazem -HCl : 300 ppm, sericin/chitosan 1:4, GA: 0.16% 
 
 
Figure ‎6-46 long-time permeation data diltiazem -HCl : 300 ppm, sericin/chitosan 1:4, GA: 0.16% 
 
y = 0.0013x - 0.0963 













y = 0.0001x - 0.077 


















Figure ‎6-48 long-time permeation data diltiazem -HCl : 200 ppm, sericin/chitosan 1:4, GA: 0.16% 
 
y = 0.00084x - 0.0582 













y = 0.0002x - 0.0388 

































y = 0.0001x - 0.394 














Figure ‎6-51 short-time permeation data diltiazem -HCl : 400 ppm, sericin/chitosan 1:4, GA: 0.24% 
 
 
Figure ‎6-52 long-time permeation data diltiazem -HCl : 400 ppm, sericin/chitosan 1:4, GA: 0.24% 
 
y = 0.002x - 0.146 














y = 0.0002x - 0.0379 




















Figure ‎6-54 long-time permeation data diltiazem -HCl : 300 ppm, sericin/chitosan 1:4, GA: 0.24% 
 
y = 0.00143x - 0.1002 













y = 0.00021x - 0.0766 














Figure ‎6-55 short-time permeation data diltiazem -HCl : 200 ppm, sericin/chitosan 1:4, GA: 0.24% 
 
 
Figure ‎6-56 long-time permeation data diltiazem -HCl : 200 ppm, sericin/chitosan 1:4, GA: 0.24% 
 
y = 0.00096x - 0.0671 















y = 0.0002x - 0.1006 
















Figure ‎6-57 short-time permeation data diltiazem -HCl : 100 ppm, sericin/chitosan 1:4, GA: 0.24% 
 
 















y = 0.00044x - 0.0279 
R2 = 0.999 
y = 0.0001x - 0.1051 














Figure ‎6-59 short-time permeation data diltiazem -HCl: 400 ppm, sericin/chitosan 1:4, GA: 0.40% 
 
 
















y = 0.0017x - 0.1412 
R2 = 0.997 
y = 0.0002x - 0.0572 














Figure ‎6-61 short-time permeation data diltiazem -HCl : 300 ppm, sericin/chitosan 1:4, GA: 0.40% 
 












y = 0.0013 - 0.106 
          R2 = 0.9994 
y = 0.00011x - 0.10093 















Figure ‎6-63 short-time permeation data diltiazem -HCl : 200 ppm, sericin/chitosan 1:4, GA: 0.40% 
 
 














y = 0.0008 - 0.068 
R2 = 0.999 
y = 0.0001x - 0. 832 
















Figure ‎6-65 short-time permeation data diltiazem -HCl : 100 ppm, sericin/chitosan 1:4, GA: 0.40% 
 
 














y = 0.0004x - 0.03341 
R2 = 0.999 
y = 0.00008x - 0.0425 

































0.40 100 86 89 2.57E-09 4.89E-08 4.75E-08 
200 85 89 2.59E-09 4.90E-08 5.37E-08 
300 84 89 2.63E-09 5.20E-08 5.25E-08 
400 82 89 2.68E-09 5.32E-08 4.88E-08 
0.24 100 63 78 2.67E-09 4.79E-08 4.69E-08 
200 70 78 2.42E-09 5.19E-08 5.17E-08 
300 70 78 2.41E-09 5.17E-08 5.15E-08 
400 73 78 2.33E-09 5.38E-08 5.38E-08 
0.16 100 73 82 2.57E-09 4.99E-08 5.19E-08 
200 69 82 2.69E-09 4.80E-08 4.97E-08 
300 74 82 2.54E-09 4.94E-08 5.05E-08 
400 74 82 2.51E-09 5.12E-08 5.58E-08 
0.08 100 76 84 2.57E-09 4.59E-08 4.79E-08 
200 79 84 2.49E-09 4.74E-08 5.27E-08 
300 79 84 2.49E-09 5.02E-08 4.85E-08 











Figure ‎6-68 long-time permeation data, nitrofurazon: 400 ppm, sericin/chitosan 1:4, GA: 0.08% 
y = 0.0259x - 0.1256 













y = 0.001x - 0.007 



















Figure ‎6-70 long-time permeation data, nitrofurazon: 300 ppm, sericin/chitosan 1:4, GA: 0.08% 
y = 0.0211x - 0.0525 















y = 0.00104x + 0.001218 
















Figure ‎6-71 short-time permeation data, nitrofurazon: 200 ppm, sericin/chitosan 1:4, GA: 0.08% 
 
 
Figure ‎6-72 long-time permeation data, nitrofurazon: 200 ppm, sericin/chitosan 1:4, GA: 0.08% 
 
y = 0.0231x - 0.0558 















y = 0.0013x + 0.0048 


















Figure ‎6-74 long-time permeation data, nitrofurazon: 100 ppm, sericin/chitosan 1:4, GA: 0.08% 
 
y = 0.0143x - 0.0618 














y = 0.0013x - 0.0379 






















Figure ‎6-76 long-time permeation data, nitrofurazon: 400 ppm, sericin/chitosan 1:4, GA: 0.16% 
 
y = 0.0338x + 0.0838 














y = 0.00104x - 0.018372 














Figure ‎6-77 short-time permeation data, nitrofurazon: 300 ppm, sericin/chitosan 1:4, GA: 0.16% 
 
 
Figure ‎6-78 long-time permeation data, nitrofurazon: 300 ppm, sericin/chitosan 1:4, GA: 0.16% 
 
y = 0.0264x - 0.0798 













y = 0.0012x + 0.0022 


















Figure ‎6-80 long-time permeation data, nitrofurazon: 200 ppm, sericin/chitosan 1:4, GA: 0.16% 
 
y = 0.025x - 0.0778 















y = 0.0011x - 0.0011 














Figure ‎6-81 short-time permeation data, nitrofurazon: 100 ppm, sericin/chitosan 1:4, GA: 0.16% 
 
 
Figure ‎6-82 long-time permeation data, nitrofurazon: 100 ppm, sericin/chitosan 1:4, GA: 0.16% 
y = 0.0147x - 0.0491 














y = 0.0011x - 0.0517 














Figure ‎6-83 short-time permeation data, nitrofurazon: 400 ppm, sericin/chitosan 1:4, GA: 0.24% 
 
 
Figure ‎6-84 long-time permeation data, nitrofurazon: 400 ppm, sericin/chitosan 1:4, GA: 0.24% 
y = 0.0574x - 0.1774 













y = 0.0017x + 0.0002 

















Figure ‎6-85 short-time permeation data, nitrofurazon: 300 ppm, sericin/chitosan 1:4, GA: 0.24% 
 
 
Figure ‎6-86 long-time permeation data, nitrofurazon: 300 ppm, sericin/chitosan 1:4, GA: 0.24% 
y = 0.0287x - 0.2606 












y = 0.0012x - 0.0099 














Figure ‎6-87 short-time permeation data, nitrofurazon: 200 ppm, sericin/chitosan 1:4, GA: 0.24% 
 
 
Figure ‎6-88 long-time permeation data, nitrofurazon: 200 ppm, sericin/chitosan 1:4, GA: 0.24% 
  
y = 0.0381x - 0.0968 













y = 0.0019x + 0.0086 

















Figure ‎6-89 short-time permeation data, nitrofurazon: 100 ppm, sericin/chitosan 1:4, GA: 0.24% 
 
 
Figure ‎6-90 long-time permeation data, nitrofurazon: 100 ppm, sericin/chitosan 1:4, GA: 0.24% 
y = 0.0152x - 0.0811 















y = 0.0013x - 0.0006 














Figure ‎6-91 short-time permeation data, nitrofurazon: 400 ppm, sericin/chitosan 1:4, GA: 0. 40% 
 
 
Figure ‎6-92 long-time permeation data, nitrofurazon: 400 ppm, sericin/chitosan 1:4, GA: 0. 40% 
 
y = 0.0574x - 0.1774 












y = 0.001667x - 0.003523 

























y = 0.0226x - 0.1244 















y = 0.001x + 0.002 



















Figure ‎6-96 long-time permeation data, nitrofurazon: 200 ppm, sericin/chitosan 1:4, GA: 0. 40% 
 
y = 0.0225x - 0.0665 














y = 0.00134x + 0.001292 























y = 0.0186x - 0.0866 














y = 0.0019x + 0.0354 






































100 4.3 110 7.82E-08 1.68E-06 1.53E-06 
200 2.5 110 1.34E-07 1.58E-06 1.53E-06 
300 2.5 110 1.34E-07 1.11E-06 1.22E-06 
400 4.8 110 7.00E-08 1.01E-06 1.18E-06 
0.16 
100 3.3 110 1.02E-07 1.92E-06 1.29E-06 
200 3 110 1.12E-07 1.64E-06 1.29E-06 
300 3 110 1.12E-07 1.42E-06 1.41E-06 
400 2.5 110 1.34E-07 1.13E-06 1.23E-06 
0.24 
100 5.3 114 6.81E-08 1.97E-06 1.58E-06 
200 2.5 86 8.22E-08 1.95E-06 1.75E-06 
300 9 111 3.80E-08 1.55E-06 1.42E-06 
400 3.1 110 1.08E-07 2.12E-06 2.01E-06 
0.40 
100 4.6 89 4.78E-08 2.16E-06 1.81E-06 
200 3 86 6.85E-08 1.35E-06 1.23E-06 
300 5.5 88 3.91E-08 9.12E-07 9.4E-07 





 7.1.4. Sorption and Desorption Experiments 
Ciprofloxacin-HCl
 
Figure ‎6-99 Sorption kinetics, ciprofloxacin-HCl: 100 ppm, GA: 0.40% 
 
 































Figure ‎6-101 Sorption kinetics, ciprofloxacin-HCl: 200 ppm, GA: 0.40% 
 
 






























Figure ‎6-103 Sorption kinetics, ciprofloxacin-HCl: 300 ppm, GA: 0.40% 
 
 






























Figure ‎6-105 Sorption kinetics, ciprofloxacin-HCl: 400 ppm, GA: 0.40% 
 
 































Figure ‎6-107 Sorption kinetics, ciprofloxacin-HCl: 400 ppm, GA: 0.24% 
 
 







































































































































Figure ‎6-115 Sorption kinetics, ciprofloxacin-HCl: 400 ppm, GA: 0.16% 
 
 































Figure ‎6-117 Sorption kinetics, ciprofloxacin-HCl: 300 ppm, GA: 0.16% 
 
 






























Figure ‎6-119 Sorption kinetics, ciprofloxacin-HCl: 200 ppm, GA: 0.16% 
 
 






























Figure ‎6-121 Sorption kinetics, ciprofloxacin-HCl: 100 ppm, GA: 0.16% 
 
 































Figure ‎6-123 Sorption kinetics, ciprofloxacin-HCl: 400 ppm, GA: 0.08% 
 
 































Figure ‎6-125 Sorption kinetics, ciprofloxacin-HCl: 300 ppm, GA: 0.08% 
 
 






























Figure ‎6-127 Sorption kinetics, ciprofloxacin-HCl: 200 ppm, GA: 0.08% 
 
 






























Figure ‎6-129 Sorption kinetics, ciprofloxacin-HCl: 100 ppm, GA: 0.08% 
 
 


































Figure ‎6-131 Sorption kinetics, diltiazem-HCl: 100 ppm, GA: 0.08% 
 






























Figure ‎6-133 Sorption kinetics, diltiazem-HCl: 200 ppm, GA: 0.08% 
 
 






























Figure ‎6-135 Sorption kinetics, diltiazem-HCl: 300 ppm, GA: 0.08% 
 






























Figure ‎6-137 Sorption kinetics, diltiazem-HCl: 400 ppm, GA: 0.08% 
 






























Figure ‎6-139 Sorption kinetics, diltiazem-HCl: 100 ppm, GA: 0.16% 
 
 































Figure ‎6-141 Sorption kinetics, diltiazem-HCl: 200 ppm, GA: 0.16% 
 
 































Figure ‎6-143 Sorption kinetics, diltiazem-HCl: 300 ppm, GA: 0.16% 
 
 































Figure ‎6-145 Sorption kinetics, diltiazem-HCl: 400 ppm, GA: 0.16% 
 
 































Figure ‎6-147 Sorption kinetics, diltiazem-HCl: 100 ppm, GA: 0.24% 
 
 






























Figure ‎6-149 Sorption kinetics, diltiazem-HCl: 200 ppm, GA: 0.24% 
 
 






























Figure ‎6-151 Sorption kinetics, diltiazem-HCl: 300 ppm, GA: 0.24% 
 
 






























Figure ‎6-153 Sorption kinetics, diltiazem-HCl: 400 ppm, GA: 0.24% 
 
 






























Figure ‎6-155 Sorption kinetics, diltiazem-HCl: 100 ppm, GA: 0.40% 
 
 






























Figure ‎6-157 Sorption kinetics, diltiazem-HCl: 200 ppm, GA: 0.40% 
 






























Figure ‎6-159 Sorption kinetics, diltiazem-HCl: 300 ppm, GA: 0.40% 
 
 






























Figure ‎6-161 Sorption kinetics, diltiazem-HCl: 400 ppm, GA: 0.40% 
 
 


































Figure ‎6-163 Sorption kinetics, nitrofurazon: 400 ppm, GA: 0.40% 
 
 






























Figure ‎6-165 Sorption kinetics, nitrofurazon: 300 ppm, GA: 0.40% 
 
 































Figure ‎6-167 Sorption kinetics, nitrofurazon: 200 ppm, GA: 0. 40% 
 
 
































Figure ‎6-169 Sorption kinetics, nitrofurazon: 100 ppm, GA: 0.40% 
 
 



































































Figure ‎6-173 Sorption kinetics, nitrofurazon: 300 ppm, GA: 0.24% 
 
 































Figure ‎6-175 Sorption kinetics, nitrofurazon: 200 ppm, GA: GA: 0.24% 
 
 






























Figure ‎6-177 Sorption kinetics, nitrofurazon: 100 ppm, GA: 0.24% 
 
 






























Figure ‎6-179 Sorption kinetics, nitrofurazon: 400 ppm, GA: 0.16% 
 
 































Figure ‎6-181 Sorption kinetics, nitrofurazon: 300 ppm, GA: 0.16% 
 
 































Figure ‎6-183 Sorption kinetics, nitrofurazon: 200 ppm, GA: 0.16% 
 
 






























Figure ‎6-185 Sorption kinetics, nitrofurazon: 100 ppm, GA: 0.16% 
 
 






























Figure ‎6-187 Sorption kinetics, nitrofurazon: 400 ppm, GA: 0.08% 
 
 
































Figure ‎6-189 Sorption kinetics, nitrofurazon: 300 ppm, GA: 0.08% 
 
 






























Figure ‎6-191 Sorption kinetics, nitrofurazon: 200 ppm, GA: 0.08% 
 
 






























Figure ‎6-193 Sorption kinetics, nitrofurazon: 100 ppm, GA: 0.08% 
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